Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 cardiovascular safety study of survodutide in adults with overweight or obesity and cardiovascular or kidney risk
CTR20234021Phase 3Completed
- Sponsor
- ——/ 勃林格殷格翰(中国)投资有限公司
- Start
- Feb 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of survodutide in obesity, sponsored by ——/ 勃林格殷格翰(中国)投资有限公司. Started Feb 2024; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on CTR20234021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234021.